Brazilian Journal of Pulmonology

ISSN (on-line): 1806-3756 | ISSN (printed): 1806-3713


Publication continuous and bimonthly

SCImago Journal & Country Rank
Advanced Search

Search Results

The search for the author or contributors found : 3 results

Retreatment of tuberculosis patients in the city of Porto Alegre, Brazil: outcomes

Desfechos do retratamento de pacientes com tuberculose com o uso do esquema 3 em Porto Alegre, Brasil

Pedro Dornelles Picon, Carlos Fernando Carvalho Rizzon, Sergio Luiz Bassanesi, Luiz Carlos Correa da Silva, Maria de Lourdes Della Giustina

J Bras Pneumol.2011;37(4):504-511

Abstract PDF PT PDF EN Portuguese Text

Objective: To describe the outcomes of retreatment in tuberculosis patients receiving the regimen known, in Brazil, as regimen 3 (streptomycin, ethambutol, ethionamide, and pyrazinamide for 3 months + ethambutol and ethionamide for 9 months) after treatment failure with the basic regimen (rifampin, isoniazid, and pyrazinamide for 2 months + rifampin and isoniazid for 4 months). Methods: A descriptive, uncontrolled, historical cohort study involving adult tuberculosis patients treated with regimen 3. We evaluated adverse drug effects, recurrence, treatment outcomes, and associated factors. Results: The study included 229 patients. The overall cure rate was 62%. For the patients who used the medications regularly and those who did not, the cure rate was 88% and 31%, respectively. Adverse events occurred in 95 patients (41.5%), and most of those events were related to the gastrointestinal tract. In the five-year follow-up period, relapse occurred in 17 cases (12.0%). Conclusions: Overall, the outcomes of treatment with regimen 3 were unsatisfactory, in part because this regimen was administered to a selected population of patients at high risk for noncompliance with treatment, as well as because it presents high rates of adverse effects, especially those related to the gastrointestinal tract, which might be caused by ethionamide. However, for those who took the medications regularly, the cure rate was satisfactory. The recurrence rate was higher than that recommended in international consensus guidelines, which might be attributable to the short (12-month) treatment period. We believe that regimen 3, extended to 18 months, represents an option for patients with proven treatment compliance.


Keywords: Tuberculosis, pulmonary/therapy; Treatment outcome; Retreatment.


Differences in the clinical and radiological presentation of intrathoracic tuberculosis in the presence or absence of HIV infection

Diferenças na apresentação clínico-radiológica da tuberculose intratorácica segundo a presença ou não de infecção por HIV

Pedro Dornelles Picon, Maria Luiza Avancini Caramori, Sérgio Luiz Bassanesi, Sandra Jungblut, Marcelo Folgierini, Nelson da Silva Porto, Carlos Fernando Carvalho Rizzon, Roberto Luiz Targa Ferreira, Tânia Mariza de Freitas, Carla Adriane Jarczewski

J Bras Pneumol.2007;33(4):429-436

Abstract PDF PT PDF EN Portuguese Text

Objective: To describe the differences in the clinical and radiological presentation of tuberculosis in the presence or absence of HIV infection. Methods: A sample of 231 consecutive adults with active pulmonary tuberculosis admitted to a tuberculosis hospital were studied, assessing HIV infection, AIDS, and associated factors, as well as re-evaluating chest X-rays. Results: There were 113 HIV-positive patients (49%) Comparing the 113 HIV-positive patients (49%) to the 118 HIV-negative patients (51%), the former presented a higher frequency of atypical pulmonary tuberculosis (pulmonary lesions accompanied by intrathoracic lymph node enlargement), hematogenous tuberculosis, and pulmonary tuberculosis accompanied by superficial lymph node enlargement, as well as presenting less pulmonary cavitation. The same was found when HIV-positive patients with AIDS were compared to those without AIDS. There were no differences between the HIV-positive patients without AIDS and the HIV-negative patients. Median CD4 counts were lower in HIV-positive patients with intrathoracic lymph node enlargement and pulmonary lesions than in the HIV-positive patients with pulmonary lesions only (47 vs. 266 cells/mm3; p < 0.0001), in HIV-positive patients with AIDS than in those without AIDS (136 vs. 398 cells/mm3; p < 0.0001) and in patients with atypical pulmonary tuberculosis than in those with other forms of tuberculosis (31 vs. 258 cells/mm3; p < 0.01). Conclusion: Atypical forms and disseminated disease predominate among patients with advanced immunosuppression. In regions where TB prevalence is high, the presence of atypical pulmonary tuberculosis or pulmonary tuberculosis accompanied by superficial lymph node enlargement should be considered an AIDS-defining condition.


Keywords: Tuberculosis, pulmonary; HIV infections; Radiography, thoracic.


Results of tuberculosis treatment with streptomycin, isoniazid, and ethambutol (scheme SHM)

Resultado do tratamento da tuberculose com estreptomicina, isoniazida e etambutol (esquema SHM)

Pedro Dornelles Picon, Maria de Lourdes Della Giustina, Carlos Fernando Carvalho Rizzon, Sérgio Luiz Bassanesi, Ana Paula Zanardo, Matheus Truccolo Michalczuk, Letícia Rebolho Dei Ricardi

J Bras Pneumol.2002;28(4):187-192

Abstract PDF PT

Aim: To evaluate the performance of an SHM scheme (streptomycin, isoniazid, and ethambutol) in an outpatient clinic routine treatment for tuberculosis. Method: Seventy-eight patients with tuberculosis whose prior treatment with the RHZ scheme (six months of rifampicin, isoniazid, and pyrazinamide) had to be discontinued due to adverse effects, or who could not receive the RHZ scheme due to high risk for liver toxicity, were treated in the outpatient clinic with the 12 month SHM scheme from 1986 to 1994, in the city of Porto Alegre, Rio Grande do Sul, Brazil. Results: Three patients (3.8%) required a scheme change due to toxicity. In the remaining 75 patients, 58 (77.3%) were cured, eight (10.7%) withdrew, five (6.7%) presented failure, and four (5.3%) died. Theoretical cure rate, which is the percent of cure of patients who regularly followed the treatment, was 95.3%. Adverse reactions were seen in 32 patients (41%), the most frequent being vestibular damage in 18 patients (23.1%). Results were compared to those obtained in the same outpatient clinic with the 12 month RHM scheme (rifampicin, isoniazid, and ethambutol), and with the six month RHZ scheme. Conclusion: The SHM scheme may be recommended as an alternative for the treatment of tuberculosis whenever the RHZ scheme cannot be indicated.




The Brazilian Journal of Pulmonology is indexed in:

Latindex Lilacs SciELO PubMed ISI Scopus Copernicus pmc


CNPq, Capes, Ministério da Educação, Ministério da Ciência e Tecnologia, Governo Federal, Brasil, País Rico é País sem Pobreza
Secretariat of the Brazilian Journal of Pulmonology
SCS Quadra 01, Bloco K, Salas 203/204 Ed. Denasa. CEP: 70.398-900 - Brasília - DF
Fone/fax: 0800 61 6218/ (55) (61) 3245 1030/ (55) (61) 3245 6218

Copyright 2019 - Brazilian Thoracic Association

Logo GN1